WO2023180471A1 - Composition for stimulating o-glcnacylation during extracorporeal circulation - Google Patents
Composition for stimulating o-glcnacylation during extracorporeal circulation Download PDFInfo
- Publication number
- WO2023180471A1 WO2023180471A1 PCT/EP2023/057528 EP2023057528W WO2023180471A1 WO 2023180471 A1 WO2023180471 A1 WO 2023180471A1 EP 2023057528 W EP2023057528 W EP 2023057528W WO 2023180471 A1 WO2023180471 A1 WO 2023180471A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- levels
- glcnacylation
- increases
- ecc
- Prior art date
Links
- 230000006271 O-GlcNAcylation Effects 0.000 title claims abstract description 59
- 239000000203 mixture Substances 0.000 title description 19
- 230000004936 stimulating effect Effects 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 54
- 238000000034 method Methods 0.000 claims abstract description 47
- 238000012360 testing method Methods 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 230000002411 adverse Effects 0.000 claims description 7
- LFTYTUAZOPRMMI-CFRASDGPSA-N UDP-N-acetyl-alpha-D-glucosamine Chemical compound O1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](NC(=O)C)[C@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-CFRASDGPSA-N 0.000 claims description 6
- LFTYTUAZOPRMMI-UHFFFAOYSA-N UNPD164450 Natural products O1C(CO)C(O)C(O)C(NC(=O)C)C1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-UHFFFAOYSA-N 0.000 claims description 6
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 6
- 230000002612 cardiopulmonary effect Effects 0.000 claims description 6
- 238000002618 extracorporeal membrane oxygenation Methods 0.000 claims description 5
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 4
- PPAIMZHKIXDJRN-FMDGEEDCSA-N (3ar,5r,6s,7r,7ar)-2-(ethylamino)-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]2O PPAIMZHKIXDJRN-FMDGEEDCSA-N 0.000 claims description 3
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 3
- 229960002442 glucosamine Drugs 0.000 claims description 3
- 238000002617 apheresis Methods 0.000 claims description 2
- 239000001569 carbon dioxide Substances 0.000 claims description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 2
- 238000002680 cardiopulmonary resuscitation Methods 0.000 claims description 2
- 238000001631 haemodialysis Methods 0.000 claims description 2
- 230000000322 hemodialysis Effects 0.000 claims description 2
- 238000002615 hemofiltration Methods 0.000 claims description 2
- 238000002616 plasmapheresis Methods 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 abstract description 14
- 238000011282 treatment Methods 0.000 abstract description 14
- 239000008280 blood Substances 0.000 abstract description 12
- 210000004369 blood Anatomy 0.000 abstract description 12
- 102000004169 proteins and genes Human genes 0.000 abstract description 10
- 108090000623 proteins and genes Proteins 0.000 abstract description 10
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 abstract description 9
- 230000004872 arterial blood pressure Effects 0.000 abstract description 9
- 150000003893 lactate salts Chemical class 0.000 abstract description 9
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 abstract description 8
- 230000000747 cardiac effect Effects 0.000 abstract description 8
- 229940109239 creatinine Drugs 0.000 abstract description 7
- 230000007423 decrease Effects 0.000 abstract description 6
- 208000027418 Wounds and injury Diseases 0.000 abstract description 4
- 230000006378 damage Effects 0.000 abstract description 3
- 208000014674 injury Diseases 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000001990 intravenous administration Methods 0.000 description 8
- 108010077991 O-GlcNAc transferase Proteins 0.000 description 7
- 102000005520 O-GlcNAc transferase Human genes 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 5
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 229960002725 isoflurane Drugs 0.000 description 5
- 230000037452 priming Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 4
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 230000004481 post-translational protein modification Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 101001120790 Caenorhabditis elegans UDP-N-acetylglucosamine-peptide N-acetylglucosaminyltransferase Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 3
- 229960002428 fentanyl Drugs 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000002397 Kinins Human genes 0.000 description 2
- 108010093008 Kinins Proteins 0.000 description 2
- 238000012313 Kruskal-Wallis test Methods 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- -1 for example Chemical class 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 150000002772 monosaccharides Chemical group 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000004768 organ dysfunction Effects 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- OYTJKRAYGYRUJK-FMCCZJBLSA-M rocuronium bromide Chemical compound [Br-].N1([C@@H]2[C@@H](O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(CC=C)CCCC2)CCOCC1 OYTJKRAYGYRUJK-FMCCZJBLSA-M 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- CBDKQYKMCICBOF-UHFFFAOYSA-N thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 description 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 238000010152 Bonferroni least significant difference Methods 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- GSXOAOHZAIYLCY-UHFFFAOYSA-N D-F6P Natural products OCC(=O)C(O)C(O)C(O)COP(O)(O)=O GSXOAOHZAIYLCY-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- 229940126137 O-GlcNAcase inhibitor Drugs 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100030122 Protein O-GlcNAcase Human genes 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- BGWGXPAPYGQALX-ARQDHWQXSA-N beta-D-fructofuranose 6-phosphate Chemical compound OC[C@@]1(O)O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O BGWGXPAPYGQALX-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 238000013132 cardiothoracic surgery Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000005794 circulatory dysfunction Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000018514 detection of nutrient Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 108010045982 hexosaminidase C Proteins 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 208000037890 multiple organ injury Diseases 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 238000012141 orotracheal intubation Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008289 pathophysiological mechanism Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Inorganic materials [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
- 229960004134 propofol Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 229960000491 rocuronium Drugs 0.000 description 1
- 229960003682 rocuronium bromide Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008718 systemic inflammatory response Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Inventors observe that the NButGT treatment increases the O-GlcNAcylation levels of cardiac proteins (p<0.05). Mean arterial pressure decreases 5 hours after ECC procedure compared to the sham group (sham: 95.7 ± 3.7; ECC: 69.8 ± 7.7; mmHg; p<0.05). The NButGT treatment tends to increase the mean arterial pressure compared to the ECC group (NButGT: 90.8 ± 10.3;mmHg; p = 0.11). ECC procedure is associated with an organism injury with an increase in lactates, creatinine, blood urea nitrogen and bicarbonates levels 5 hours after ECC procedure (p<0.05). NButGT treatment tends to reduce lactates and creatinine levels and decreases blood urea nitrogen and arterial bicarbonates 5 hours after ECC procedure (p<0.05). Accordingly, the present invention relates to a method for increasing O-GlcNAcylation levels in a subject having or is susceptible to have an extracorporeal circulation comprising administering said subject with a therapeutically effective amount of a compound that increases O-GlcNAcylation levels.
Description
METHOD AND COMPOSITION FOR STIMULATING O-GLCNACYLATION DURING EXTRACORPOREAL CIRCULATION
FIELD OF THE INVENTION:
The invention is in the field of cardiology, more particularly the invention relates to method and composition for stimulating O-GlcNAcylation during extracorporeal circulation.
BACKGROUND OF THE INVENTION:
O-GlcNAcylation is a form of post-translational protein modification. It involves attachment of the monosaccharide N-acetylglucosamine (GlcNAc) to serine and threonine residues in nuclear, mitochondrial and cytoplasmic proteins in different organisms. O- GlcNAcylation is a reversible process catalysed by O-GlcNAc transferase (OGT) and O- GlcNAcase (OGA) which adds and removes the GlcNAc moiety, respectively. O- GlcNAcylation plays an important role in many, if not all, cellular processes.
Extracorporeal circulation (ECC) is an essential component in critical care and cardiothoracic surgery with for example the cardiopulmonary bypass (CPB) (Reynolds and Annich, 2011), the extracorporeal membrane oxygenation (ECMO), the extracorporeal life support (ECLS) or the extracorporeal carbon di oxy de removal (ECCO2R) but is associated with complex adverse event (Al-Fares et al., 2019). It comprises microcirculatory and metabolic disorders, activation of the complement, kinin, fibrin pathways and inflammation (Casey, 1993; Esper et al., 2014) and bacterial endotoxins translocation from the patient's digestive system (Kats et al., 2011) potentially leading to organs dysfunction and poor patients’ outcomes. Unfortunately, multi-organ dysfunction occurs relatively frequently, to varying degrees (Esper et al., 2014) and no real prevention means, or treatment are available. A gap still remains to improve patients’ outcomes and there is a need to study the pathophysiological mechanisms. Animal model mimicking pathophysiology of CPB or ECMOZECLS and reproducing multiple organ injuries are needed.
CPB is a common procedure to maintain body perfusion during cardiac surgery. It is associated with a systemic inflammatory response, hemostasis and circulatory dysfunction that can lead to organ dysfunction and seldomly to death. Previous studies shows that glutamine reduces myocardial damage after coronary revascularization under cardiopulmonary bypass (Chavez-Tostado et al, 2017. Lomivorotov et al, 2011), or that pyruvate modifies metabolic flux and nutrient sensing during ECMO (Ledee et al, 2015). However, these studies do not teach or suggest a direct relationship between an increase in O-GlcNAcylation levels and a
cardioprotective effect. O-GlcNAcylation is a post-translational modification modulated in response to stress in different acute and chronic situations. The inflammation and tissue stress consecutive to CPB are associated with an increase in blood O-GlcNAcylation levels 5 hours after CPB. Thus, there is a need to reduce the inflammation and tissue stress during a CBP.
SUMMARY OF THE INVENTION:
The invention relates to a method for increasing O-GlcNAcylation levels in a subject having or is susceptible to have an extracorporeal circulation comprising administering said subject with a therapeutically effective amount of a compound that increases O-GlcNAcylation levels. In particular, the invention is defined by the claims.
DETAILED DESCRIPTION OF THE INVENTION:
Inventors observe that the NButGT treatment increases the O-GlcNAcylation levels of cardiac proteins (p<0.05) (Figure 1). Mean arterial pressure decreases 5 hours after ECC procedure compared to the sham group (sham: 95.7 ± 3.7; ECC: 69.8 ± 7.7; mmHg; p<0.05) (Figure 3 A). The NButGT treatment tends to increase the mean arterial pressure compared to the ECC group (NButGT: 90.8 ± 10.3; mmHg; p = 0.11) (Figure 3 A). ECC procedure is associated with an organism injury with an increase in lactates, creatinine, blood urea nitrogen and bicarbonates levels 5 hours after ECC procedure (p<0.05) (Figure 3B-3E). NButGT treatment tends to reduce lactates and creatinine levels and decreases blood urea nitrogen and arterial bicarbonates 5 hours after ECC procedure (p<0.05) (Figure 3B-3E).
Accordingly, in a first aspect, the invention relates to a method for increasing O- GlcNAcylation levels in a subject having or is susceptible to have an extracorporeal circulation comprising administering said subject with a therapeutically effective amount of a compound that increases O-GlcNAcylation levels.
In other words, the invention relates to a method for reducing or preventing adverse effect of extracorporeal circulation in a subject comprising administering to said subject a therapeutically effective amount of a compound that increases O-GlcNAcylation levels.
In other words, the invention relates to a compound that increases O-GlcNAcylation levels for use for reducing or preventing adverse effect of extracorporeal circulation in a subject in need thereof.
As used herein, the term “extracorporeal circulation” refers to the circulation of blood outside of the body through a machine that temporarily assumes an organ's functions, for example, through a heart-lung machine or artificial kidney. In a particular embodiment, the extracorporeal circulation is performed during apheresis, autotransfusion, hemodialysis, hemofiltration, plasmapheresis, extracorporeal carbon dioxide removal, extracorporeal cardiopulmonary resuscitation, extracorporeal membrane oxygenation (ECMO) or cardiopulmonary bypass.
As used herein, the term “adverse effect of extracorporeal circulation” has its general meaning in the art and refers to potential complication caused by extracorporeal circulation. Typically adverse effects of circulation include but are not limited to microcirculatory and metabolic disorders, activation of the complement, kinin, fibrin pathways and inflammation (Casey, 1993; Esper et al., 2014) and bacterial endotoxins translocation from the patient's digestive system (Kats et al., 2011), which can lead to organs dysfunction and poor subject’s outcomes. Adverse effects of extracorporeal circulation include also organ failure and acute atrial fibrillation.
As used herein, the term “subject” refers to any mammals, such as a rodent, a feline, a canine, and a primate. Particularly, in the present invention, the subject is a human having or susceptible to have extracorporeal circulation. In other words, the subject is a human requiring or susceptible to requires an extracorporeal circulation.
As used herein, the term “increasing” refers to an increase in O-GlcNAcylation levels. In the context of the invention (extracorporeal circulation), an increase in O-GlcNAcylation levels allows to reduce circulating lactates, creatinin, blood urea nitrogen (BUN) and arterial bicarbonates.
As used herein, the term “O-GlcNAcylation levels” also known as O-N-acetyl glucosaminylation refers to a reversible posttranslational modification (PTM) that involves the addition of the monosaccharide P-D-Nacetylglucosamine to serine and threonine residues of proteins. Protein O-GlcNAcylation is added by O-GlcNAc transferase (OGT), and the O- GlcNAc group on proteins can be removed via the P-N-acetylglucosaminidase (O-GlcNAcase, OGA). O-GlcNAcylation is regulated dynamically by these two enzymes and by the intracellular concentration of UDP-GlcNAc, a product of glucose metabolism through the hexosamine biosynthetic pathway (HBP).
As used herein, the term “compound that increases O-GlcNAcylation levels” refers to a natural or synthetic compound that has a biological effect to increase the levels of O- GlcNAcylation. More particularly, such compound is capable of reduce the production of lactates, creatinine and blood urea nitrogen (BUN).
In a particular embodiment, the compound that increases O-GlcNAcylation levels is an inhibitor of P-N-acetylglucosaminidase (OGA).
As used herein, the term “P-N-acetylglucosaminidase”, also known as OGA or O- GlcNAcase, has its general meaning in the art and refers to enzyme which hydrolyse N- acetylglucosamine-containing oligosaccharides and proteins.
As used herein, the term “inhibitor of P-N-acetylglucosaminidase” refers to a natural or synthetic compound that has a biological effect to inhibit the activity of OGA and thus increase the levels of O-GlcNAcylation.
In a particular embodiment, the inhibitor of P-N-acetylglucosaminidase is a peptide, peptidomimetic or a small organic molecule.
In a particular embodiment, the inhibitor of P-N-acetylglucosaminidase is is 1,2- dideoxy-2z -propyl- a -d-glucopyranoso-[2, 1-D]- A 2-thiazoline (NButGT) and its derivatives. The CAS number of NButGT is 863918-55-2.
In a particular embodiment, the inhibitor of P-N-acetylglucosaminidase is (3aR,5R,6S,7R,7aR)-2-(ethylamino)-3a,6,7,7a-tetrahydro-5-(hydroxymethyl)-5H-Pyrano[3,2- d]thiazole-6,7-diol) (ThiametG) and its derivatives. The CAS number of ThiametGis 1009816- 48-1.
In a particular embodiment, the compound that increases O-GlcNAcylation levels is a peptide, peptidomimetic or a small organic molecule.
In a particular embodiment, the compound that increases O-GlcNAcylation levels is a small organic molecule. The term “small organic molecule” refers to a molecule of a size comparable to those organic molecules generally used in pharmaceuticals. The term excludes biological macromolecules (e.g., proteins, nucleic acids, etc.). Preferred small organic molecules range in size up to about 5000 Da, more preferably up to 2000 Da, and most preferably up to about 1000 Da.
In a particular embodiment, the compound that increases O-GlcNAcylation levels is 1,2- dideoxy-2z -propyl- a -d-glucopyranoso-[2, 1-D]- A 2-thiazoline (NButGT) and its derivatives. The CAS number of NButGT is 863918-55-2.
In a particular embodiment, the compound that increases O-GlcNAcylation levels is (3aR,5R,6S,7R,7aR)-2-(ethylamino)-3a,6,7,7a-tetrahydro-5-(hydroxymethyl)-5H-Pyrano[3,2- d]thiazole-6,7-diol) (ThiametG) and its derivatives. The CAS number of ThiametGis 1009816- 48-1.
In a particular embodiment, the compound that increases O-GlcNAcylation levels is a compound that increases the Uridine diphosphate N-acetylglucosamine (UDP-GlcNAc).
As used herein, the term “UDP-GlcNAc” refers to a nucleotide sugar and a coenzyme in metabolism. It is synthesized de novo from glucose by the hexosamine synthesis pathway (HBP), but can also be produced via salvage pathways.
In a particular embodiment, compound that increases O-GlcNAcylation levels is a compound that increases the hexosamine biosynthesis pathway flux that bypasses glutamine/fructose-6-phosphate amidotransferase 2.
In a particular embodiment, the compound that increases O-GlcNAcylation levels is glutamine or glucosamine.
As used herein the terms "administering" or "administration" refer to the act of injecting or otherwise physically delivering a substance as it exists outside the body (e.g., a compound that increases O-GlcNAcylation levels) into the subject, such as by mucosal, intradermal, intravenous, subcutaneous, intramuscular delivery and/or any other method of physical delivery described herein or known in the art. When a disease, or a symptom thereof, is being treated, administration of the substance typically occurs after the onset of the disease or symptoms thereof. When a disease or symptoms thereof, are being prevented, administration of the substance typically occurs before the onset of the disease or symptoms thereof.
A “therapeutically effective amount” is intended for a minimal amount of active agent which is necessary to impart therapeutic benefit to a subject. For example, a "therapeutically effective amount" to a subject is such an amount which induces, ameliorates or otherwise causes an improvement in the pathological symptoms, disease progression or physiological conditions associated with or resistance to succumbing to a disorder. It will be understood that the total daily usage of the compounds of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular subject will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of the specific compound 15 employed; the specific composition employed, the age, body weight, general health, sex and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific
compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts. For example, it is well within the skill of the art to start doses of the compound at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved. However, the daily dosage of the products may be varied over a wide range from 0.01 to 1,000 mg per adult per day. Typically, the compositions contain 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 250 and 500 mg of the active ingredient for the symptomatic adjustment of the dosage to the subject to be treated. A medicament typically contains from about 0.01 mg to about 500 mg of the active ingredient, preferably from 1 mg to about 100 mg of the active ingredient. An effective amount of the drug is ordinarily supplied at a dosage level from 0.0002 mg/kg to about mg/kg of body weight per day, especially from about 0.001 mg/kg to 7 mg/kg of body weight per day.
The compound that increases O-GlcNAcylation levels as described above may be combined with pharmaceutically acceptable excipients, and optionally sustained-release matrices, such as biodegradable polymers, to form pharmaceutical compositions.
Accordingly, in a second aspect, the invention relates to a pharmaceutical composition comprising the compound that increases O-GlcNAcylation levels as described above and excipients.
"Pharmaceutically" or "pharmaceutically acceptable" refer to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to a mammal, especially a human, as appropriate. A pharmaceutically acceptable carrier or excipient refers to a non-toxic solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The pharmaceutical compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, transdermal, local or rectal administration, the active principle, alone or in combination with another active principle, can be administered in a unit administration form, as a mixture with conventional pharmaceutical supports, to animals and human beings. Suitable unit administration forms comprise oral-route forms such as tablets, gel capsules, powders, granules and oral suspensions or solutions, sublingual and buccal administration forms, aerosols, implants, subcutaneous, transdermal, topical, intraperitoneal, intramuscular, intravenous, subdermal, transdermal, intrathecal and intranasal administration forms and rectal administration forms. Typically, the pharmaceutical compositions contain vehicles which are pharmaceutically acceptable for a formulation capable of being injected. These may be in particular isotonic, sterile, saline solutions (monosodium or disodium phosphate, sodium, potassium, calcium or magnesium
chloride and the like or mixtures of such salts), or dry, especially freeze-dried compositions which upon addition, depending on the case, of sterilized water or physiological saline, permit the constitution of injectable solutions. The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions; formulations including sesame oil, peanut oil or aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. Solutions comprising compounds of the invention as free base or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms. The polypeptide (or nucleic acid encoding thereof) can be formulated into a composition in a neutral or salt form. Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like. The carrier can also be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetables oils. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminium monostearate and gelatin. Sterile injectable solutions are prepared by incorporating the active polypeptides in the required amount in the appropriate solvent with several of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion
medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective. The formulations are easily administered in a variety of dosage forms, such as the type of injectable solutions described above, but drug release capsules and the like can also be employed. For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. In this connection, sterile aqueous media which can be employed will be known to those of skill in the art in light of the present disclosure. For example, one dosage could be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or inj ected at the proposed site of infusion. Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.
In a particular embodiment, the invention relates to a pharmaceutical composition comprising NButGT for use during extracorporeal circulation.
In a particular embodiment, the invention relates to a pharmaceutical composition comprising ThiametG for use during extracorporeal circulation.
In a particular embodiment, the invention relates to a pharmaceutical composition comprising glutamine or glucosamine for use during extracorporeal circulation.
A further object of the present invention relates to a method of screening a compound that increases O-GlcNAcylation levels comprising i) providing a test compound and ii) determining the ability of said test compound to increase O-GlcNAcylation levels.
Any biological assay well known in the art could be suitable for determining the ability of the test compound to increase O-GlcNAcylation levels. In some embodiments, the assay first comprises determining the ability of the test compound to bind to a protein O-GlcNAcylation. In some embodiments, a population of cells is then contacted and activated so as to determine the ability of the test compound to increase O-GlcNAcylation. In particular, the effect triggered by the test compound is determined relative to that of a population of immune cells incubated in parallel in the absence of the test compound or in the presence of a control agent either of which is analogous to a negative control condition. The term "control substance", "control
agent", or "control compound" as used herein refers a molecule that is inert or has no activity relating to an ability to modulate a biological activity or expression. It is to be understood that test compounds capable of increasing O-GlcNAcylation levels, as determined using in vitro methods described herein, are likely to exhibit similar modulatory capacity in applications in vivo. Typically, the test compound is small organic molecules. For example, the test compound according to the invention may be selected from a library of compounds previously synthesised, or a library of compounds for which the structure is determined in a database, or from a library of compounds that have been synthesised de novo. In some embodiments, the test compound may be selected form small organic molecules.
The invention will be further illustrated by the following figures and examples. However, these examples and figures should not be interpreted in any way as limiting the scope of the present invention.
FIGURES:
Figure 1: NButGT treatment increases cardiac O-GlcNAc levels. Evaluation by western blot of the O-GlcNAcylation levels of cardiac proteins in Sham, ECC and NButGT rats 5 hours after extubating. Sham: Sham procedure consisted of the whole protocol without priming the pump of ECC; ECC: The animals are cannulated and undergo an extracorporeal circulation procedure. Sham: Sham procedure consisted of the whole protocol without priming the pump of ECC; NButGT: The animals are cannulated and undergo an extracorporeal circulation procedure and received intravenous NButGT injections (lOmg/kg) to increase O- GlcNAc levels. Quantification of O-GlcNAcylation levels is normalized to stain free. Results are expressed as box and whisker. Statistical significance was assessed by Kruskal-Wallis test with uncorrected Dunn’s post-test (**: p<0.01).
Figure 2: Impact of ECC and NButGt on OGA and OGT cardiac expression. Evaluation by western blot of the cardiac expression of OGA (A) and OGT (B) in Sham, ECC and NButGT rats 5 hours after extubating. Sham: Sham procedure consisted of the whole protocol without priming the pump of ECC. ECC: The animals are cannulated and undergo an extracorporeal circulation procedure. NButGT: The animals are cannulated and undergo an extracorporeal circulation procedure and received intravenous NButGT injections (lOmg/kg) to increase O-GlcNAc levels. Quantification of O-GlcNAcylation levels is normalized to stain free. Results are expressed as box and whisker. Statistical significance was assessed by Kruskal- Wallis test with uncorrected Dunn’s post-test (**: p<0.01) n= 4 to 11.
Figure 3: NButGT treatments limits the organ dysfunction. Mean arterial pressure throughout ECC and 5 hours after extubating in Sham, ECC and NButGT rats (A). Evaluation of lactates levels (B), creatininemia (C) and blood urea nitrogen levels (D) in Sham, ECC and NButGT rats 5 hours after extubating. Arterial bicarbonates levels at the start, the end of ECC and 5 hours after extubating in Sham, ECC and NButGT rats (E). ECC: The animals are cannulated and undergo an extracorporeal circulation procedure. Sham: Sham procedure consisted of the whole protocol without priming the pump of ECC; NButGT: The animals are cannulated and undergo an extracorporeal circulation procedure and received intravenous NButGT injections (lOmg/kg) to increase O-GlcNAc levels. Results are expressed as box and whisker. Statistical significance was assessed by 2-Way ANOVA with Bonferroni post hoc test. *: p < 0.05 ECC vs Sham; $: p < 0.05 NButGT vs Sham; #: p < 0.05 NButGT vs ECC
EXAMPLE:
Material & Methods
For the ECC group, animals were anaesthetized with 5% isoflurane/FiO2 1.0 in an induction box and maintained with a mask with 2% isoflurane. A rectal probe and a heating surgery platform (Harvard Apparatus, Molliston, MA) were used to control and maintain rats’ temperature at 37.5 ± 1°C during surgery and 36.5 ± 1°C during ECC. A bolus of fentanyl (12 pg.kg-1; Fentadon, Dechra, France), allowing pain relief during procedures, was slowly administered to avoid any respiratory failure. Prior to surgery, orotracheal intubation (14G cannula; Instech laboratories, USA) allowed anesthesia maintenance with 1.5% isoflurane/FiO2 1.0. Rats were curarized with an iv injection of Rocuronium bromide (Esmeron, Img/kg; Hospira, France) and mechanical ventilation was set (Harvard model 683, Harvard-apparatus, USA) with a tidal volume of 6 mL/kg and a respiratory rate of 58 ± 2 cycles/min. Three cannulas, filled with heparinized Ringer Lactate (30 UI.mL'1) were respectively inserted in the left femoral artery (PE- 10; Instech laboratories, USA) to monitor arterial blood pressure, in the right jugular vein (6Fr, Vygon, France) and in the left carotid (PE-50; Instech-laboratories, Plymouth, USA). Unfractionated heparin (300 Ul/kg; Panpharma, France) was injected in the jugular vein before ECC. ECC was initiated and pump speed was adjusted to reach the mean arterial pressure (MAP) minimum target of 60 mmHg. ECC have been facilitated with Phenylephrine infusion (Renaudin, France). An infusion of propofol (30 mg. kg'1. hr'1; PropoVet, Abott, France) combined with fentanyl (2 pg. kg'1. hr'1) replaced isoflurane Anesthesia during ECC. The venous route was clamped and the blood contained in the circuit was restituted before stopping the pump. Catheters were removed and vessels were tied with 5/0 silk threads (B. Braun, France)
and wounds have been stitched (5/0 non-resorbable Vycril). Rats were finally weaned from anesthesia and extubated at the onset of signs of resumption of spontaneous respiratory activity. Rats received subcutaneous fluid therapy (10 mL.kg'1, NaCl 0.9%, B. Braun, France) mixed with buprenorphine (0.03 mg. kg'1, Buprecare®, Axience, France) and placed in a heating chamber. Five hours after extubating (H+5), hemodynamic was monitored under isoflurane anesthesia (1.5%, FiO2 1.0). Sham procedure consisted of the whole protocol without priming the pump of ECC. For the NButGT group, animals received intravenous NButGT injections (lOmg/kg) prior the surgery (at the same time that the bolus of fentanyl) and at the weaning from anesthesia.
Results
The ECC procedure does not impact the cardiac protein O-GlcNAcylation levels (Figure 1). We observe that the NButGT treatment, an OGA inhibitor, increases the O-GlcNAcylation levels of cardiac proteins (p<0.05) (Figure 1). We also observed that NButGT treatment increases also the myocardial OGA expression (Sham l±0.08; ECC 1 ,04±0.16; ECC + NButGT 6.8±2.9; p<0.01; n=4 to 11) (Figure 2A). On contrary, there was no evidence of variation in OGT expression across the protocol (Sham 1 ± 0.08; CEC 0.9 ± 0.04; CEC + NButGT 0.9 ± 0.09; p > 0.05; n=4 to 11) (Figure 2B). Mean arterial pressure decreases 5 hours after ECC procedure compared to the sham group (sham: 95.7 ± 3.7; ECC: 69.8 ± 7.7; mmHg; p<0.05) (Figure 3 A). The NButGT treatment tends to increase the mean arterial pressure compared to the ECC group (NButGT: 90.8 ± 10.3; mmHg; p = 0.11) (Figure 3 A). ECC procedure is associated with an organism injury with an increase in lactates, creatinine, blood urea nitrogen and bicarbonates levels 5 hours after ECC procedure (p<0.05) (Figure 3B-3E). NButGT treatment tends to reduce lactates and creatinine levels and decreases blood urea nitrogen and arterial bicarbonates 5 hours after ECC procedure (p<0.05) (Figure 3B-3E).
REFERENCES:
Reynolds MM, Annich GM. The artificial endothelium. Organogenesis. 2011 Jan- Mar;7(l):42-9. doi: 10.4161/org.7.1.14029.
Al-Fares AA, Randhawa VK, Englesakis M, McDonald MA, Nagpal AD, Estep JD, Soltesz EG, Fan E. Optimal Strategy and Timing of Left Ventricular Venting During Veno- Arterial Extracorporeal Life Support for Adults in Cardiogenic Shock: A Systematic Review and Meta- Analysis. Circ Heart Fail. 2019 Nov; 12(1 l):e006486.
Casey LC. Role of cytokines in the pathogenesis of cardiopulmonary-induced multisystem organ failure. Ann Thorac Surg. 1993 Nov;56(5 Suppl):S92-6.
Esper SA, Subramaniam K, Tanaka KA. Pathophysiology of Cardiopulmonary Bypass: Current Strategies for the Prevention and Treatment of Anemia, Coagulopathy, and Organ Dysfunction. Semin Cardiothorac Vase Anesth. 2014 Jun;18(2): 161-76.
Kats S, Schonberger JP, Brands R, Seinen W, van Oeveren W. Endotoxin release in cardiac surgery with cardiopulmonary bypass: pathophysiology and possible therapeutic strategies. An update. Eur J Cardiothorac Surg. 2011 Apr;39(4):451-8.
Chavez-Tostado M, Carrillo-Llamas F, Martinez-Gutierrez PE, Alvarado-Ramirez A, Lopez-Taylor JG, Vasquez- Jimenez JC, Fuentes-Orozco C, Rendon-Felix J, Irusteta-Jimenez L, Calil-Romero VC, Ramirez-Jimenez JA, Michel-Espinoza LR, Contreras-Lopez CK, Cuesta-Marquez LA, Gonzalez-Ojeda A. Oral glutamine reduces myocardial damage after coronary revascularization under cardiopulmonary bypass. A randomized clinical trial. Nutr Hosp. 2017 Mar 30;34(2):277-283.
Lomivorotov VV, Efremov SM, Shmirev VA, Ponomarev DN, Lomivorotov VN, Karaskov AM. Glutamine is cardioprotective in patients with ischemic heart disease following cardiopulmonary bypass. Heart Surg Forum. 2011 Dec;14(6):E384-8.
Ledee DR, Kajimoto M, O'Kelly Priddy CM, Olson AK, Isern N, Robillard-Frayne I, Des Rosiers C, Portman MA. Pyruvate modifies metabolic flux and nutrient sensing during extracorporeal membrane oxygenation in an immature swine model. Am J Physiol Heart Circ Physiol. 2015 Jul l;309(l):H137-46.
Claims
1. A method for increasing O-GlcNAcylation levels in a subject having an extracorporeal circulation comprising administering said subject with a therapeutically effective amount of a compound that increases O-GlcNAcylation levels.
2. A method for reducing or preventing adverse effect of extracorporeal circulation in a subject comprising administering to said subject with a therapeutically effective amount of a compound that increases O-GlcNAcylation levels.
3. The method according to claim 1 or 2, wherein the extracorporeal circulation is performed during apheresis, autotransfusion, hemodialysis, hemofiltration, plasmapheresis, extracorporeal carbon dioxide removal, extracorporeal cardiopulmonary resuscitation, extracorporeal membrane oxygenation (ECMO) or cardiopulmonary bypass.
4. The method according to claim 1 or 2, wherein the extracorporeal circulation is performed during cardiopulmonary bypass (CPB).
5. The method according to any one of claim 1 to 4, wherein, the compound that increases O-GlcNAcylation levels is l,2-dideoxy-2'-propyl-a-d-glucopyranoso-[2,l-D]-A2'- thiazoline (NButGT).
6. The method according to any one of claim 1 to 4, wherein, the compound that increases O-GlcNAcylation levels is (3aR,5R,6S,7R,7aR)-2-(ethylamino)-3a,6,7,7a-tetrahydro- 5-(hydroxymethyl)-5H-Pyrano[3,2-d]thiazole-6,7-diol) (ThiametG).
7. The method according to any one of claim 1 to 4, wherein, the compound that increases O-GlcNAcylation levels is a compound that increases Uridine diphosphate N- acetylglucosamine (UDP-GlcNAc).
8. The method according to any one of claim 1 to 4, wherein, the compound that increases O-GlcNAcylation levels is glutamine or glucosamine.
A pharmaceutical composition comprising the compound that increases O- GlcNAcylation levels according to claims 1 to 8 for use during extracorporeal circulation. The pharmaceutical composition according to claim 9, wherein the extracorporeal circulation is performed during cardiopulmonary bypass (CPB). A method of screening a compound that increases O-GlcNAcylation levels comprising i) providing a test compound and ii) determining the ability of said test compound to increase O-GlcNAcylation levels.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22305357.0 | 2022-03-24 | ||
EP22305357 | 2022-03-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023180471A1 true WO2023180471A1 (en) | 2023-09-28 |
Family
ID=81307362
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/057528 WO2023180471A1 (en) | 2022-03-24 | 2023-03-23 | Composition for stimulating o-glcnacylation during extracorporeal circulation |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023180471A1 (en) |
-
2023
- 2023-03-23 WO PCT/EP2023/057528 patent/WO2023180471A1/en unknown
Non-Patent Citations (16)
Title |
---|
"ESICM LIVES 2022: part 1", INTENSIVE CARE MEDICINE EXPERIMENTAL, BIOMED CENTRAL LTD, LONDON, UK, vol. 10, no. 2, 19 October 2022 (2022-10-19), pages 1 - 243, XP021309151, DOI: 10.1186/S40635-022-00468-1 * |
AL-FARES AARANDHAWA VKENGLESAKIS MMCDONALD MANAGPAL ADESTEP JDSOLTESZ EGFAN E: "Optimal Strategy and Timing of Left Ventricular Venting During Veno-Arterial Extracorporeal Life Support for Adults in Cardiogenic Shock: A Systematic Review and Meta-Analysis", CIRC HEART FAIL, vol. 12, no. 11, November 2019 (2019-11-01), pages e006486 |
CADIET JULIEN ET AL: "French Intensive Care Society, International congress - Réanimation 2016: Beneficial cardiovascular effects of O-GlcNAc stimulation in early phase of septic shock", vol. 6, no. S1, 1 June 2016 (2016-06-01), pages 1 - 236, XP055959198, Retrieved from the Internet <URL:http://link.springer.com/article/10.1186/s13613-016-0114-z/fulltext.html> [retrieved on 20220908], DOI: 10.1186/s13613-016-0114-z * |
CAS , no. 1009816-48-1 |
CASEY LC: "Role of cytokines in the pathogenesis of cardiopulmonary-induced multisystem organ failure", ANN THORAC SURG, vol. 56, November 1993 (1993-11-01), pages S92 - 6 |
CHÁVEZ-TOSTADO MARIANA ET AL: "Oral glutamine reduces myocardial damage after coronary revascularization under cardiopulmonary bypass. A randomized clinical trial", vol. 34, no. 2, 30 March 2017 (2017-03-30), ES, pages 277, XP055958844, ISSN: 0212-1611, Retrieved from the Internet <URL:http://revista.nutricionhospitalaria.net/index.php/nh/article/viewFile/519/538> [retrieved on 20220908], DOI: 10.20960/nh.519 * |
CHAVEZ-TOSTADO MCARRILLO-LLAMAS FMARTINEZ-GUTIERREZ PEALVARADO-RAMIREZ ALOPEZ-TAYLOR JGVASQUEZ-JIMENEZ JCFUENTES-OROZCO CRENDON-FE: "Oral glutamine reduces myocardial damage after coronary revascularization under cardiopulmonary bypass", A RANDOMIZED CLINICAL TRIAL, vol. 34, no. 2, 30 March 2017 (2017-03-30), pages 277 - 283 |
ESPER SASUBRAMANIAM KTANAKA KA: "Pathophysiology of Cardiopulmonary Bypass: Current Strategies for the Prevention and Treatment of Anemia, Coagulopathy, and Organ Dysfunction", SEMIN CARDIOTHORAC VASC ANESTH, vol. 18, no. 2, June 2014 (2014-06-01), pages 161 - 76 |
FERRON MARINE ET AL: "Protein O-GlcNAcylation in Cardiac Pathologies: Past, Present, Future", FRONTIERS IN ENDOCRINOLOGY, vol. 9, 15 January 2019 (2019-01-15), XP055959125, DOI: 10.3389/fendo.2018.00819 * |
KATS SSCHONBERGER JPBRANDS RSEINEN WVAN OEVEREN W: "Endotoxin release in cardiac surgery with cardiopulmonary bypass: pathophysiology and possible therapeutic strategies. An update", EUR J CARDIOTHORAC SURG, vol. 39, no. 4, April 2011 (2011-04-01), pages 451 - 8, XP028161361, DOI: 10.1016/j.ejcts.2010.06.011 |
LECOMTE J. ET AL: "Modulation of carbonic anhydrase activity with O-GlcNacylation stimulation: A new approach to prevent post-cardiopulmonary bypass multi-organ dysfunction", ARCHIVES OF CARDIOVASCULAR DISEASES SUPPLEMENTS, vol. 15, no. 1, 1 January 2023 (2023-01-01), AMSTERDAM, NL, pages 117, XP093055031, ISSN: 1878-6480, DOI: doi.org/10.1016/j.acvdsp.2022.10.226 * |
LEDEE DOLENA R. ET AL: "Pyruvate modifies metabolic flux and nutrient sensing during extracorporeal membrane oxygenation in an immature swine model", AMERICAN JOURNAL OF PHYSIOLOGY HEART AND CIRCULATORY PHYSIOLOGY, vol. 309, no. 1, 1 July 2015 (2015-07-01), US, pages H137 - H146, XP055959193, ISSN: 0363-6135, DOI: 10.1152/ajpheart.00011.2015 * |
LEDEE DRKAJIMOTO MO'KELLY PRIDDY CMOLSON AKISERN NROBILLARD-FRAYNE IDES ROSIERS CPORTMAN MA: "Pyruvate modifies metabolic flux and nutrient sensing during extracorporeal membrane oxygenation in an immature swine model", AM J PHYSIOL HEART CIRC PHYSIOL., vol. 309, no. 1, 1 July 2015 (2015-07-01), pages H137 - 46, XP055959193, DOI: 10.1152/ajpheart.00011.2015 |
LOMIVOROTOV VLADIMIR V. ET AL: "Glutamine Is Cardioprotective in Patients with Ischemic Heart Disease following Cardiopulmonary Bypass", vol. 14, no. 6, 13 December 2011 (2011-12-13), US, pages 384, XP055958898, ISSN: 1098-3511, Retrieved from the Internet <URL:http://cardenjennings.metapress.com/index/R45NVRM1173P24W4.pdf> [retrieved on 20220908], DOI: 10.1532/HSF98.20111074 * |
LOMIVOROTOV VVEFREMOV SMSHMIREV VAPONOMAREV DNLOMIVOROTOV VNKARASKOV AM: "Glutamine is cardioprotective in patients with ischemic heart disease following cardiopulmonary bypass", HEART SURG FORUM, vol. 14, no. 6, December 2011 (2011-12-01), pages E384 - 8 |
REYNOLDS MMANNICH GM: "The artificial endothelium", ORGANOGENESIS, vol. 7, no. 1, January 2011 (2011-01-01), pages 42 - 9 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0706398B1 (en) | Pharmaceutical composition containing heparin, heparin fragments or their derivatives in combination with glycerol esters | |
JP2002534384A (en) | Treatment and prevention of reactive oxygen metabolite-mediated cell damage | |
JP5409710B2 (en) | Composition for reducing postoperative complications of cardiopulmonary bypass (CPB) surgery | |
CN114392228A (en) | Long-lasting formulations of melatonin injections exhibiting long-term stability | |
US11963940B2 (en) | Parenteral esmolol formulation | |
JP6389172B2 (en) | Use of antithrombin in extracorporeal membrane oxygenator | |
CN109417016B (en) | Glutaric acid compounds for the treatment of ischemia-reperfusion injury | |
JP3253302B2 (en) | Parenteral solution containing 3-dialkylaminoethoxybenzoyl-benzofuran | |
WO2023180471A1 (en) | Composition for stimulating o-glcnacylation during extracorporeal circulation | |
JPH03135918A (en) | Immune-activating agent | |
US20210330750A1 (en) | Lactate-protected hypoglycemia to treat glycolysis dependent pathological conditions, in particular cancer | |
EP2106791A1 (en) | Glutamine or glutamine-containing dipeptide in a specific dosage for the treatment of inflammation | |
Monteiro et al. | Severe diltiazem poisoning treated with hyperinsulinaemia-euglycaemia and lipid emulsion | |
EP2040689B1 (en) | Solution comprising n-acetylcysteine and gluconic acid, and methods to reduce, treat and/or prevent oxidative stress and cell activation | |
KR20060002795A (en) | Compositions and methods for preventing and treating endotoxin-related diseases and conditions | |
MXPA01006698A (en) | Solution of n- o(p-pivaloyloxbenzenesulfonylamino)benzoyl glycine monosodium salt tetra-hydrate and drug product thereof. | |
CN108310371B (en) | Blood fat reducing pharmaceutical composition and application thereof | |
Eliopoulos et al. | Contribution of animal models in the search for effective therapy for endocarditis due to enterococci with high-level resistance to gentamicin | |
KR20080096829A (en) | Intravenous antiviral treatments | |
GB2421908A (en) | Medicament for treatment of inflammatory diseases | |
JP3022915B2 (en) | Cancer metastasis inhibitor | |
WO1996037205A1 (en) | Remedy for endotoxinemia and multiple organ failure induced thereby | |
JPS62149616A (en) | Phylaxis intensifier | |
JP2004503472A (en) | Administer anti-endotoxin by bolus or intermittent intravenous infusion | |
Kalenahalli et al. | Severe bradycardia caused by octreotide in an adolescent: A case report |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23713379 Country of ref document: EP Kind code of ref document: A1 |